Carfilzomib (BioDeep_00000710891)
代谢物信息卡片
Carfilzomib
化学式: C40H57N5O7 (719.4257771999999)
中文名称: 卡非佐米
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4
InChI: InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XG - Proteasome inhibitors
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2160 - Proteasome Inhibitor
C471 - Enzyme Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:65347
- KEGGdrug: D08880
- PubChem: 11556711
- DrugBank: DB08889
- ChEMBL: CHEMBL451887
- CAS: 868540-17-4
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yuxuan Chen, Rou Peng, Yi Qian, Yizhou Lu, Liyao Chen, Meiling Yu, Minjiao Jiang, Wei Wu, Shengfeng Lu. Genome-wide analysis in PC6 electroacupuncture to ameliorate carfilzomib-induced cardiotoxicity in mice.
Gene.
2024 Mar; 897(?):148090. doi:
10.1016/j.gene.2023.148090. [PMID: 38110043] - Marwa M Qadri, Mohammad Firoz Alam, Zenat A Khired, Reem O Alaqi, Amani A Khardali, Moudi M Alasmari, Ahmad S S Alrashah, Hisham M A Muzafar, Abdullah M Qahl. Thymoquinone Ameliorates Carfilzomib-Induced Renal Impairment by Modulating Oxidative Stress Markers, Inflammatory/Apoptotic Mediators, and Augmenting Nrf2 in Rats.
International journal of molecular sciences.
2023 Jun; 24(13):. doi:
10.3390/ijms241310621. [PMID: 37445797] - Ru Si, Ping Hai, Yongbiao Zheng, Nanxin Liu, Jin Wang, Qingqing Zhang, Yanchen Li, Xiaoyan Pan, Jie Zhang. Discovery of novel PROTACs based on multi-targeted angiogenesis inhibitors.
Bioorganic & medicinal chemistry letters.
2023 05; 87(?):129275. doi:
10.1016/j.bmcl.2023.129275. [PMID: 37030566] - Akira Kawasaki, Hirokazu Murakami, Takaaki Chou, Masaru Matsushita, Masahiro Kizaki. Post-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma.
Future oncology (London, England).
2022 Aug; 18(24):2661-2674. doi:
10.2217/fon-2022-0259. [PMID: 35815645] - Arthi Sridhar, Binoy Yohannan, Johncy John Kachira, Sameeksha Bhama. Severe pulmonary toxicity related to carfilzomib use: a rare but serious side effect.
BMJ case reports.
2022 Jul; 15(7):. doi:
10.1136/bcr-2022-251173. [PMID: 35787495] - Ayako Muramatsu, Tsutomu Kobayashi, Yuka Kawaji-Kanayama, Hitoji Uchiyama, Nana Sasaki, Nobuhiko Uoshima, Mitsushige Nakao, Ryoichi Takahashi, Kazuho Shimura, Hiroto Kaneko, Miki Kiyota, Katsuya Wada, Yoshiaki Chinen, Koichi Hirakawa, Shin-Ichi Fuchida, Chihiro Shimazaki, Shinsuke Mizutani, Taku Tsukamoto, Yuji Shimura, Masafumi Taniwaki, Satoshi Teramukai, Junya Kuroda. Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma.
Leukemia & lymphoma.
2022 Jul; 63(7):1678-1685. doi:
10.1080/10428194.2022.2038373. [PMID: 35147475] - Xuan Wu, Le Wang, Yan-Neng Xu, Jian-Li Chen, Kathy Qian Luo, Ming-Heng Yuan, Jie Li, Gang Yuan, Ze-Yun Gu, Xiao-Hui Jia, Xiuping Chen, Xiao-Ming Zhu, Ruibin Jiang. Chemo-Phototherapy with Carfilzomib-Encapsulated TiN Nanoshells Suppressing Tumor Growth and Lymphatic Metastasis.
Small (Weinheim an der Bergstrasse, Germany).
2022 07; 18(29):e2200522. doi:
10.1002/smll.202200522. [PMID: 35748183] - Takayuki Fujii, Shin Ohara, Tomoyuki Uchida, Morihiro Inoue, Masao Hagihara, Ko Miyamoto. [Rapid response of secondary plasma cell leukemia after carfilzomib and dexamethasone therapy].
[Rinsho ketsueki] The Japanese journal of clinical hematology.
2022; 63(2):111-113. doi:
10.11406/rinketsu.63.111. [PMID: 35264500] - Angela Rago, Agostina Siniscalchi, Attilio Tordi, Cristina Andrizzi, Selenia Campagna, Tommaso Caravita di Toritto. Pulmonary arterial hypertension in a patient with multiple myeloma during carfilzomib treatment: in search of better management.
Tumori.
2021 Dec; 107(6):NP37-NP40. doi:
10.1177/0300891621990427. [PMID: 33525991] - Xavier Leleu, Ajai Chari, Shambavi Richard, Monica Khurana, Akeem Yusuf, Saad Z Usmani. A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly.
Expert review of hematology.
2021 12; 14(12):1049-1058. doi:
10.1080/17474086.2021.1955343. [PMID: 34546844] - Bethany E Monteith, Christopher P Venner, Matthew C Cheung, Joe Pater, Lois Shepherd, Harriet Richardson, Donna Reece, Engin Gul, Marc Lalancette, Vincent Castonguay, Vishal Kukreti, Rodger Tiedemann, Chai Phua, Sita Bhella, Jill Dudebout, Max Sherry, Hope Yen, Bingshu E Chen, Annette E Hay. A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
European journal of haematology.
2021 Sep; 107(3):333-342. doi:
10.1111/ejh.13671. [PMID: 34053112] - Aseel Alsouqi, Muhammad Khan, Binod Dhakal, Liping Du, Shelton Harrell, Parameswaran Hari, Robert F Cornell. KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma.
Clinical lymphoma, myeloma & leukemia.
2021 08; 21(8):526-535. doi:
10.1016/j.clml.2021.03.013. [PMID: 33985931] - Roy Sriwattanakomen, Qingyong Xu, Moses Demehin, Michael A Shullo, Massimo Mangiola, Gavin W Hickey, Christopher M Sciortino, Edward T Horn, Mary E Keebler, Adriana Zeevi. Impact of carfilzomib-based desensitization on heart transplantation of sensitized candidates.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
2021 07; 40(7):595-603. doi:
10.1016/j.healun.2021.03.001. [PMID: 33785250] - Philippe Moreau, Razi Ghori, Mohammed Farooqui, Patricia Marinello, Jesus San Miguel. Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study.
British journal of haematology.
2021 07; 194(1):e48-e51. doi:
10.1111/bjh.17448. [PMID: 34114211] - Philippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, Marie-Laure Risse, Gaelle Asset, Sandrine Macé, Thomas Martin. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Lancet (London, England).
2021 06; 397(10292):2361-2371. doi:
10.1016/s0140-6736(21)00592-4. [PMID: 34097854] - Srikanth R Polusani, Valerie Cortez, Javier Esparza, Huynh Nga Nguyen, Hongxin Fan, Gopalrao V N Velagaleti, Matthew J Butler, Marsha C Kinney, Babatunde O Oyajobi, Samy L Habib, Reto Asmis, Edward A Medina. Oxidatively modified low-density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma.
International journal of cancer.
2021 06; 148(12):3032-3040. doi:
10.1002/ijc.33497. [PMID: 33521927] - Monika K Prelowska, Dawid Mehlich, M Talha Ugurlu, Hanna Kedzierska, Aleksandra Cwiek, Artur Kosnik, Klaudia Kaminska, Anna A Marusiak, Dominika Nowis. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Cancer letters.
2021 06; 507(?):13-25. doi:
10.1016/j.canlet.2021.02.020. [PMID: 33713737] - Christopher P Venner, Richard LeBlanc, Irwindeep Sandhu, Darrell White, Andrew R Belch, Donna E Reece, Christine Chen, Sean Dolan, Marc Lalancette, Martha Louzada, Andrea Kew, Arleigh McCurdy, Bethany Monteith, Tony Reiman, Gail McDonald, Max Sherry, Engin Gul, Bingshu E Chen, Annette E Hay. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial.
American journal of hematology.
2021 05; 96(5):552-560. doi:
10.1002/ajh.26147. [PMID: 33650179] - Marquita Camilleri, Maria Cuadrado, Elizabeth Phillips, William Wilson, Richard Jenner, Gavin Pang, Sumaiya Kamora, Matthew Streetly, Rakesh Popat, Ceri Bygrave, Roger Owen, James Cavenagh, Mike Chapman, Jonathan Sive, Lydia Eccersley, Michael Sheaff, Reuben Benjamin, Karthik Ramasamy, Gordon Cook, Andres Virchis, Selina J Chavda, Laura Clifton-Hadley, Marie Anne Scully, Kwee Yong. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
British journal of haematology.
2021 05; 193(4):750-760. doi:
10.1111/bjh.17377. [PMID: 33650100] - Hira S Mian, Mark A Fiala, Larysa Sanchez, Ravi Vij, Tanya M Wildes. Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the 'real world'.
Annals of hematology.
2021 May; 100(5):1261-1266. doi:
10.1007/s00277-021-04420-3. [PMID: 33475778] - Gioacchino Li Cavoli, Anxur Merenda, Onofrio Schillaci, Camillo Carollo, Carmela Zagarrigo, Franca Servillo, Mattia Palmeri, Tancredi Vincenzo Li Cavoli. The Safety of Carfilzomib Therapy in Patients on Long-Term Hemodialysis and Multiple Myeloma.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.
2021 May; 32(3):896-897. doi:
10.4103/1319-2442.336794. [PMID: 35102941] - Miquel Blasco, Alexandra Martínez-Roca, Luis G Rodríguez-Lobato, Adriana Garcia-Herrera, Laura Rosiñol, Pedro Castro, Sara Fernández, Luis F Quintana, María T Cibeira, Joan Bladé, Carlos Fernández de Larrea, Natalia Tovar, Raquel Jimenez, Esteban Poch, Elena Guillen, Josep M Campistol, Enric Carreras, Maribel Diaz-Ricart, Marta Palomo. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy.
British journal of haematology.
2021 04; 193(1):181-187. doi:
10.1111/bjh.16796. [PMID: 32469083] - Bernard Regidor, Regina Swift, Benjamin Eades, Marsiye Emamy-Sadr, Fadi Tarhini, Tanya M Spektor, James R Berenson. Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.
Annals of hematology.
2021 Apr; 100(4):1079-1085. doi:
10.1007/s00277-020-04351-5. [PMID: 33237342] - Illias Tazi. [Antineoplasic drug repurposing in hematology for COVID-19 treatment].
Bulletin du cancer.
2021 Apr; 108(4):435-437. doi:
10.1016/j.bulcan.2020.12.009. [PMID: 33663776] - Yael C Cohen, Mor Zada, Shuang-Yin Wang, Chamutal Bornstein, Eyal David, Adi Moshe, Baoguo Li, Shir Shlomi-Loubaton, Moshe E Gatt, Chamutal Gur, Noa Lavi, Chezi Ganzel, Efrat Luttwak, Evgeni Chubar, Ory Rouvio, Iuliana Vaxman, Oren Pasvolsky, Mouna Ballan, Tamar Tadmor, Anatoly Nemets, Osnat Jarchowcky-Dolberg, Olga Shvetz, Meirav Laiba, Ofer Shpilberg, Najib Dally, Irit Avivi, Assaf Weiner, Ido Amit. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.
Nature medicine.
2021 03; 27(3):491-503. doi:
10.1038/s41591-021-01232-w. [PMID: 33619369] - Juan Du, Baijun Fang, Jian Li, Jie Jin, Shunqing Wang, Dehui Zou, Zhen Cai, Hongxiang Wang, Jianda Hu, Wei Li, Chengcheng Fu, Zonghong Shao, Zhongjun Xia, Peng Liu, Ting Niu, En-Tzu Tang, Amy S Kimball, Jian Hou, Wenming Chen. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
International journal of hematology.
2021 Mar; 113(3):422-429. doi:
10.1007/s12185-020-03044-z. [PMID: 33389656] - Alicia Darwin, Leonger Malpica, Jugraj Dhanoa, Hamza Hashmi. Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success.
BMJ case reports.
2021 Feb; 14(2):. doi:
10.1136/bcr-2020-239091. [PMID: 33637496] - Mohammed Isaac Abu Zaanona, Priyank Patel. Plasma cell leukaemia with t(11;14) not responsive to venetoclax.
BMJ case reports.
2021 Jan; 14(1):. doi:
10.1136/bcr-2020-238641. [PMID: 33495184] - Michael Rassner, Rebecca Baur, Ralph Wäsch, Mario Schiffer, Johanna Schneider, Andreas Mackensen, Monika Engelhardt. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
BMC nephrology.
2021 01; 22(1):32. doi:
10.1186/s12882-020-02226-5. [PMID: 33461512] - Paul M Schroder, Robin Schmitz, Zachary W Fitch, Brian Ezekian, Janghoon Yoon, Ashley Y Choi, Miriam Manook, Andrew Barbas, Frank Leopardi, Mingqing Song, Alton B Farris, Bradley Collins, Jean Kwun, Stuart J Knechtle. Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model.
Kidney international.
2021 01; 99(1):161-172. doi:
10.1016/j.kint.2020.08.020. [PMID: 32898569] - Yanmei Zhao, Lei Xu, Jiankang Zhang, Mengmeng Zhang, Jingyi Lu, Ruoyu He, Jianjun Xi, Rangxiao Zhuang, Jia Li, Yubo Zhou. Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
Bioorganic & medicinal chemistry.
2021 01; 29(?):115867. doi:
10.1016/j.bmc.2020.115867. [PMID: 33223460] - Marquita Camilleri, Jonathan Sive, William Wilson, Gavin Pang, Richard Jenner, Elizabeth Phillips, Rakesh Popat, Karthik Ramasamy, Ceri Bygrave, Tushhar Dadaga, Matthew Streetly, James Cavenagh, Mike Chapman, Sally Barrington, Lucy Pike, Roger Owen, Laura Clifton-Hadley, Kwee Yong. COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.
British journal of haematology.
2021 01; 192(1):e14-e16. doi:
10.1111/bjh.17168. [PMID: 33222153] - Despina Fotiou, Maria Roussou, Charikleia Gakiopoulou, Erasmia Psimenou, Maria Gavriatopoulou, Magdalini Migkou, Nikolaos Kanellias, Ioanna Dialoupi, Evangelos Eleutherakis-Papaiakovou, Stavroula Giannouli, Christina Delavinia, Kostantinos Efstathiou, Sofoklis Kontogiannis, Evangelos Terpos, Meletios A Dimopoulos, Efstathios Kastritis. Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients.
Blood cancer journal.
2020 11; 10(11):109. doi:
10.1038/s41408-020-00381-4. [PMID: 33149167] - Takuro Yoshimura, Yoshiki Hayashi, Katsujun Shimizu, Naoko Yagi, Minako Tsutsumi, Yosuke Nakaya, Hoyuri Fuseya, Mirei Horiuchi, Masahiro Yoshida, Takafumi Nakao, Takeshi Inoue, Takahisa Yamane. Diagnosis of a difficult to differentiate case of early-onset hyperviscosity syndrome caused by IgM type multiple myeloma: a case report.
International journal of hematology.
2020 Nov; 112(5):741-745. doi:
10.1007/s12185-020-02917-7. [PMID: 32572827] - Shaji K Kumar, Susanna J Jacobus, Adam D Cohen, Matthias Weiss, Natalie Callander, Avina K Singh, Terri L Parker, Alexander Menter, Xuezhong Yang, Benjamin Parsons, Pankaj Kumar, Prashant Kapoor, Aaron Rosenberg, Jeffrey A Zonder, Edward Faber, Sagar Lonial, Kenneth C Anderson, Paul G Richardson, Robert Z Orlowski, Lynne I Wagner, S Vincent Rajkumar. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
The Lancet. Oncology.
2020 10; 21(10):1317-1330. doi:
10.1016/s1470-2045(20)30452-6. [PMID: 32866432] - Junmei Wang. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study.
Journal of chemical information and modeling.
2020 06; 60(6):3277-3286. doi:
10.1021/acs.jcim.0c00179. [PMID: 32315171] - Somedeb Ball, Tapas Ranjan Behera, Faiz Anwer, Rajshekhar Chakraborty. Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials.
Annals of hematology.
2020 Jun; 99(6):1265-1271. doi:
10.1007/s00277-020-04062-x. [PMID: 32382772] - Khadega A Abuelgasim, Noha Alherz, Ayman Alhejazi, Moussab Damlaj. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
Journal of medical case reports.
2020 Apr; 14(1):54. doi:
10.1186/s13256-020-02376-y. [PMID: 32321588] - Manon Sapet, Ludovic Fouillet, Elisabeth Daguenet, Blandine Laurent, Denis Guyotat, Caroline Le Jeune. [Proteinuria in multiple myeloma: Be careful to iatrogeny].
Bulletin du cancer.
2020 Apr; 107(4):519-520. doi:
10.1016/j.bulcan.2020.01.014. [PMID: 32178835] - Giulia Palazzo. [Treatment of early relapsed plasma cells leukemia after unrelated bone marrow transplant with KRD (carfilzomib, lenalidomide and dexamethasone): a case report.].
Recenti progressi in medicina.
2020 Mar; 111(3):160-166. doi:
10.1701/3315.32858. [PMID: 32157264] - Sydney X Lu. Modern treatments and future directions for newly diagnosed multiple myeloma patients.
Best practice & research. Clinical haematology.
2020 03; 33(1):101151. doi:
10.1016/j.beha.2020.101151. [PMID: 32139016] - Chutima Kunacheewa, Elisabet E Manasanch. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
Best practice & research. Clinical haematology.
2020 03; 33(1):101152. doi:
10.1016/j.beha.2020.101152. [PMID: 32139017] - E Steve Woodle, Simon Tremblay, Paul Brailey, Alin Girnita, Rita R Alloway, Bruce Aronow, Nupur Dasgupta, Frederic Ebstein, Peter-Michael Kloetzel, Min Jae Lee, Kyung B Kim, Harinder Singh, James J Driscoll. Proteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
2020 02; 20(2):399-410. doi:
10.1111/ajt.15634. [PMID: 31595669] - Simon Tremblay, James J Driscoll, Adele Rike-Shields, David A Hildeman, Rita R Alloway, Alin L Girnita, Paul A Brailey, E Steve Woodle. A prospective, iterative, adaptive trial of carfilzomib-based desensitization.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
2020 02; 20(2):411-421. doi:
10.1111/ajt.15613. [PMID: 31550069] - Masuho Saburi, Masao Ogata, Yasuhiro Soga, Yoshiyuki Kondo, Ryo Kurimoto, Kazuhito Itani, Kazuhiro Kohno, Hiroki Uchida, Toshiyuki Nakayama. Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.
Journal of clinical and experimental hematopathology : JCEH.
2020 ; 60(1):17-20. doi:
10.3960/jslrt.19031. [PMID: 32224561] - Takami Haruyama, Masuho Saburi, Hitohiro Sasaki, Yuji Umeda, Akiko Kudo, Noritaka Uno. [Carfilzomib-induced renal impairment with albuminuria in a patient with relapsed/refractory multiple myeloma].
[Rinsho ketsueki] The Japanese journal of clinical hematology.
2020; 61(12):1667-1669. doi:
10.11406/rinketsu.61.1667. [PMID: 33441518] - Sofia Pizzato Scomazzon, Anna Riccio, Silvia Santopolo, Giulia Lanzilli, Marta Coccia, Antonio Rossi, M Gabriella Santoro. The Zinc-Finger AN1-Type Domain 2a Gene Acts as a Regulator of Cell Survival in Human Melanoma: Role of E3-Ligase cIAP2.
Molecular cancer research : MCR.
2019 12; 17(12):2444-2456. doi:
10.1158/1541-7786.mcr-19-0243. [PMID: 31540997] - Brian Ezekian, Paul M Schroder, Michael S Mulvihill, Andrew Barbas, Bradley Collins, Kyle Freischlag, Janghoon Yoon, John S Yi, Felicitas Smith, Danae Olaso, Frances M Saccoccio, Sallie Permar, Alton B Farris, Jean Kwun, Stuart J Knechtle. Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients.
Journal of the American Society of Nephrology : JASN.
2019 12; 30(12):2399-2411. doi:
10.1681/asn.2019030304. [PMID: 31658991] - Elshad Hasanov, Rebecca S S Tidwell, Pablo Fernandez, Lauren Park, Charla McMichael, Nizar M Tannir, Eric Jonasch. Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma.
Clinical genitourinary cancer.
2019 12; 17(6):451-456. doi:
10.1016/j.clgc.2019.07.003. [PMID: 31439537] - Zuzana Pokorna, Eduard Jirkovsky, Marketa Hlavackova, Hana Jansova, Anna Jirkovska, Olga Lencova-Popelova, Petra Brazdova, Jan Kubes, Dita Sotakova-Kasparova, Yvona Mazurova, Michaela Adamcova, Lucie Vostatkova, Kristyna Holzerova, Frantisek Kolar, Tomas Simunek, Martin Sterba. In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline.
Clinical science (London, England : 1979).
2019 08; 133(16):1827-1844. doi:
10.1042/cs20190139. [PMID: 31409729] - Naif O Al-Harbi, Faisal Imam, Mohammed M Al-Harbi, Othman A Al-Shabanah, Moureq Rashed Alotaibi, Homood M As Sobeai, Muhammad Afzal, Imran Kazmi, Ammar Cherkess Al Rikabi. Rutin inhibits carfilzomib-induced oxidative stress and inflammation via the NOS-mediated NF-κB signaling pathway.
Inflammopharmacology.
2019 Aug; 27(4):817-827. doi:
10.1007/s10787-018-0550-5. [PMID: 30600471] - Maria Chaudhry, Raphael Steiner, Catherine Claussen, Krina Patel, Hans Lee, Donna Weber, Sheeba Thomas, Chun Feng, Behrang Amini, Robert Orlowski, Lei Feng, Elisabet E Manasanch. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia.
Leukemia & lymphoma.
2019 04; 60(4):964-970. doi:
10.1080/10428194.2018.1508668. [PMID: 30227761] - Seiichi Okabe, Yuko Tanaka, Tetsuzo Tauchi, Kazuma Ohyashiki. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
Annals of hematology.
2019 Mar; 98(3):723-733. doi:
10.1007/s00277-018-3547-7. [PMID: 30430191] - Faisal Imam, Naif O Al-Harbi, Mohammed M Al-Harbi, Wajhul Qamar, Khaldoon Aljerian, Osamah Mohammed Belali, Sary Alsanea, Ahmed Z Alanazi, Khalid Alhazzani. Apremilast ameliorates carfilzomib-induced pulmonary inflammation and vascular injuries.
International immunopharmacology.
2019 Jan; 66(?):260-266. doi:
10.1016/j.intimp.2018.11.023. [PMID: 30500623] - Samuel Guzman, Sumire Kitahara. Spindle cell lesion in the bone marrow.
Blood.
2018 09; 132(10):1085. doi:
10.1182/blood-2018-05-849596. [PMID: 30190353] - Sourav Banerjee, Chenggong Ji, Joshua E Mayfield, Apollina Goel, Junyu Xiao, Jack E Dixon, Xing Guo. Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Proceedings of the National Academy of Sciences of the United States of America.
2018 08; 115(32):8155-8160. doi:
10.1073/pnas.1806797115. [PMID: 29987021] - Ross Tomlinson. Multiple myeloma: Updated approach to management in 2018.
Australian journal of general practice.
2018 08; 47(8):526-529. doi:
10.31128/ajgp-01-18-4473. [PMID: 30114882] - Philippe Moreau, Maria-Victoria Mateos, James R Berenson, Katja Weisel, Antonio Lazzaro, Kevin Song, Meletios A Dimopoulos, Mei Huang, Anita Zahlten-Kumeli, A Keith Stewart. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
The Lancet. Oncology.
2018 07; 19(7):953-964. doi:
10.1016/s1470-2045(18)30354-1. [PMID: 29866475] - Mingfei Zhang, Linwei Lu, Man Ying, Huitong Ruan, Xiaoyi Wang, Huan Wang, Zhilan Chai, Songli Wang, Changyou Zhan, Jun Pan, Weiyue Lu. Enhanced Glioblastoma Targeting Ability of Carfilzomib Enabled by a DA7R-Modified Lipid Nanodisk.
Molecular pharmaceutics.
2018 06; 15(6):2437-2447. doi:
10.1021/acs.molpharmaceut.8b00270. [PMID: 29734808] - Harris Sultan, Clint Kellogg, Jaafar El-Annan. Retinal Pigment Epithelium Tears in a 67-Year-Old Man.
JAMA ophthalmology.
2018 05; 136(5):583-584. doi:
10.1001/jamaophthalmol.2017.4445. [PMID: 29423507] - Alessandro Allegra, Antonio Speciale, Maria Sofia Molonia, Letterio Guglielmo, Caterina Musolino, Guido Ferlazzo, Gregorio Costa, Antonella Saija, Francesco Cimino. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
Toxicology in vitro : an international journal published in association with BIBRA.
2018 Mar; 47(?):186-194. doi:
10.1016/j.tiv.2017.12.001. [PMID: 29223572] - A Besse, S C Stolze, L Rasche, N Weinhold, G J Morgan, M Kraus, J Bader, H S Overkleeft, L Besse, C Driessen. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Leukemia.
2018 02; 32(2):391-401. doi:
10.1038/leu.2017.212. [PMID: 28676669] - Massimo Offidani, Laura Corvatta, Silvia Gentili. Triplet vs. doublet drug regimens for managing multiple myeloma.
Expert opinion on pharmacotherapy.
2018 02; 19(2):137-149. doi:
10.1080/14656566.2017.1418856. [PMID: 29265901] - Masaki Ri. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
[Rinsho ketsueki] The Japanese journal of clinical hematology.
2018 ; 59(10):2162-2168. doi:
10.11406/rinketsu.59.2162. [PMID: 30305522] - Yasuo Aota, Akihiko Gotoh, Yuko Okuda, Tadahiro Honda, Naoki Watanabe, Jun Ando, Norio Komatsu. [Recurrent amylase-producing multiple myeloma responding to pomalidomide and carfilzomib-containing therapies].
[Rinsho ketsueki] The Japanese journal of clinical hematology.
2018 ; 59(7):865-871. doi:
10.11406/rinketsu.59.865. [PMID: 30078795] - Jee Sun Min, Jiseon Kim, Jung Ho Kim, Doyun Kim, Yu Fen Zheng, Ji Eun Park, Wooin Lee, Soo Kyung Bae. Quantitative determination of carfilzomib in mouse plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis.
2017 Nov; 146(?):341-346. doi:
10.1016/j.jpba.2017.08.048. [PMID: 28918323] - Tristan M Sissung, Cody J Peer, Neha Korde, Sham Mailankody, Dickran Kazandjian, David J Venzon, Ola Landgren, William D Figg. Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.
Cancer chemotherapy and pharmacology.
2017 Jul; 80(1):217-221. doi:
10.1007/s00280-017-3323-8. [PMID: 28488026] - Hang Quach, Darrell White, Andrew Spencer, P Joy Ho, Divaya Bhutani, Mike White, Sandeep Inamdar, Chris Morris, Ying Ou, Martin Gyger. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study.
Cancer chemotherapy and pharmacology.
2017 Jun; 79(6):1067-1076. doi:
10.1007/s00280-017-3287-8. [PMID: 28424963] - Joshua Richter, Noa Biran, Narjust Duma, David H Vesole, David Siegel. Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.
Hematological oncology.
2017 Jun; 35(2):246-251. doi:
10.1002/hon.2290. [PMID: 27018162] - C R Ensor, S A Yousem, M Marrari, M R Morrell, M Mangiola, J M Pilewski, J D'Cunha, S R Wisniewski, R Venkataramanan, A Zeevi, J F McDyer. Proteasome Inhibitor Carfilzomib-Based Therapy for Antibody-Mediated Rejection of the Pulmonary Allograft: Use and Short-Term Findings.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
2017 May; 17(5):1380-1388. doi:
10.1111/ajt.14222. [PMID: 28173620] - Elisabet E Manasanch, Carlos Fernández de Larrea, Adriana Zingone, Seth M Steinberg, Mary Kwok, Nishant Tageja, Manisha Bhutani, Dickran Kazandjian, Mark Roschewski, Peter Wu, George Carter, Diamond Zuchlinski, Marcia Mulquin, Liz Lamping, Rene Costello, Deborah Burton, Lindsay A Gil, William D Figg, Irina Maric, Katherine R Calvo, Constance Yuan, Maryalice Stetler-Stevenson, Neha Korde, Ola Landgren. Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.
Leukemia & lymphoma.
2017 03; 58(3):639-645. doi:
10.1080/10428194.2016.1214953. [PMID: 27687480] - Harisios Tjionas, Amit K Gupta. Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2017 Mar; 23(2):152-156. doi:
10.1177/1078155215626788. [PMID: 26786028] - Rangxiao Zhuang, Lixin Gao, Xiaoqing Lv, Jianjun Xi, Li Sheng, Yanmei Zhao, Ruoyu He, Xiaobei Hu, Yidan Shao, Xuwang Pan, Shourong Liu, Weiwei Huang, Yubo Zhou, Jia Li, Jiankang Zhang. Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
European journal of medicinal chemistry.
2017 Jan; 126(?):1056-1070. doi:
10.1016/j.ejmech.2016.12.034. [PMID: 28027531] - Rimda Wanchoo, Ala Abudayyeh, Mona Doshi, Amaka Edeani, Ilya G Glezerman, Divya Monga, Mitchell Rosner, Kenar D Jhaveri. Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Clinical journal of the American Society of Nephrology : CJASN.
2017 01; 12(1):176-189. doi:
10.2215/cjn.06100616. [PMID: 27654928] - Ji Eun Park, Se-Eun Chun, Derek Reichel, Jee Sun Min, Su-Chan Lee, Songhee Han, Gongmi Ryoo, Yunseok Oh, Shin-Hyung Park, Heon-Min Ryu, Kyung Bo Kim, Ho-Young Lee, Soo Kyung Bae, Younsoo Bae, Wooin Lee. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
PloS one.
2017; 12(3):e0173247. doi:
10.1371/journal.pone.0173247. [PMID: 28273121] - Massimo Nabissi, Maria Beatrice Morelli, Massimo Offidani, Consuelo Amantini, Silvia Gentili, Alessandra Soriani, Claudio Cardinali, Pietro Leoni, Giorgio Santoni. Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.
Oncotarget.
2016 Nov; 7(47):77543-77557. doi:
10.18632/oncotarget.12721. [PMID: 27769052] - Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis, Meletios A Dimopoulos. Current treatments for renal failure due to multiple myeloma.
Expert opinion on pharmacotherapy.
2016 Nov; 17(16):2165-2177. doi:
10.1080/14656566.2016.1236915. [PMID: 27646819] - Faisal Imam, Naif O Al-Harbi, Mohammad Matar Al-Harbi, Mushtaq Ahmad Ansari, Mashal M Almutairi, Musaad Alshammari, Talal Saad Almukhlafi, Mohd Nazam Ansari, Khaldoon Aljerian, Sheikh Fayaz Ahmad. Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats.
Toxicology mechanisms and methods.
2016 Nov; 26(9):700-708. doi:
10.1080/15376516.2016.1236425. [PMID: 27785949] - N E Scholpa, R T Kolli, M Moore, R D Arnold, T C Glenn, B S Cummings. Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer.
Chemico-biological interactions.
2016 Oct; 258(?):21-9. doi:
10.1016/j.cbi.2016.08.010. [PMID: 27543423] - Irene Riz, Teresa S Hawley, Jeffrey W Marsal, Robert G Hawley. Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming.
Oncotarget.
2016 Oct; 7(41):66360-66385. doi:
10.18632/oncotarget.11960. [PMID: 27626179] - Jonathan J Hogan, Brendan M Weiss. Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.
Clinical journal of the American Society of Nephrology : CJASN.
2016 09; 11(9):1681-91. doi:
10.2215/cjn.03160316. [PMID: 27416775] - Ibrahim Qaqish, Ilana M Schlam, Harini A Chakkera, Rafael Fonseca, Jill Adamski. Carfilzomib: A cause of drug associated thrombotic microangiopathy.
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
2016 Jun; 54(3):401-4. doi:
10.1016/j.transci.2016.03.002. [PMID: 27017313] - David J Newman. Developing natural product drugs: Supply problems and how they have been overcome.
Pharmacology & therapeutics.
2016 06; 162(?):1-9. doi:
10.1016/j.pharmthera.2015.12.002. [PMID: 26706239] - Falk Hiepe, Andreas Radbruch. Plasma cells as an innovative target in autoimmune disease with renal manifestations.
Nature reviews. Nephrology.
2016 Apr; 12(4):232-40. doi:
10.1038/nrneph.2016.20. [PMID: 26923204] - Pieter Sonneveld, Annemiek Broijl. Treatment of relapsed and refractory multiple myeloma.
Haematologica.
2016 Apr; 101(4):396-406. doi:
10.3324/haematol.2015.129189. [PMID: 27033237] - Jonghoon Park, Eok Park, Cheol-Kyu Jung, Seung-Wan Kang, Byung Gyu Kim, Youngjoo Jung, Tae Hun Kim, Ji-Young Lim, Sung-Eun Lee, Chang-Ki Min, Kwang-Ai Won. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
BMC cancer.
2016 Mar; 16(?):247. doi:
10.1186/s12885-016-2285-2. [PMID: 27012957] - A Rosenthal, J Luthi, M Belohlavek, K M Kortüm, F Mookadam, A Mayo, R Fonseca, P L Bergsagel, C B Reeder, J R Mikhael, A K Stewart. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?.
Blood cancer journal.
2016 Jan; 6(?):e384. doi:
10.1038/bcj.2015.112. [PMID: 26771810] - Shaun Rosebeck, Mattina M Alonge, Malathi Kandarpa, Anoop Mayampurath, Samuel L Volchenboum, Jagoda Jasielec, Dominik Dytfeld, Sean P Maxwell, Stephanie J Kraftson, Dilara McCauley, Sharon Shacham, Michael Kauffman, Andrzej J Jakubowiak. Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
Molecular cancer therapeutics.
2016 Jan; 15(1):60-71. doi:
10.1158/1535-7163.mct-15-0488. [PMID: 26637366] - G Shay, L Hazlehurst, C C Lynch. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Journal of molecular medicine (Berlin, Germany).
2016 Jan; 94(1):21-35. doi:
10.1007/s00109-015-1345-4. [PMID: 26423531] - Matthew R Sullivan, Alexey V Danilov, Frederick Lansigan, Nancy M Dunbar. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.
Journal of clinical apheresis.
2015 Oct; 30(5):308-10. doi:
10.1002/jca.21371. [PMID: 25413611] - Steven P Treon. How I treat Waldenström macroglobulinemia.
Blood.
2015 Aug; 126(6):721-32. doi:
10.1182/blood-2015-01-553974. [PMID: 26002963] - Rimda Wanchoo, Seyyar Khan, Jonathan E Kolitz, Kenar D Jhaveri. Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2015 Aug; 21(4):313-6. doi:
10.1177/1078155214531804. [PMID: 24748581] - Irene Riz, Teresa S Hawley, Robert G Hawley. KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models.
Oncotarget.
2015 Jun; 6(17):14814-31. doi:
10.18632/oncotarget.4530. [PMID: 26109433] - Amit Mehta, Lisa Zhang, Myriem Boufraqech, Yaqin Zhang, Dhaval Patel, Min Shen, Electron Kebebew. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
Endocrine-related cancer.
2015 Jun; 22(3):319-29. doi:
10.1530/erc-14-0510. [PMID: 25972243] - Mark A Perazella, Hassan Izzedine. New drug toxicities in the onco-nephrology world.
Kidney international.
2015 May; 87(5):909-17. doi:
10.1038/ki.2015.30. [PMID: 25671763] - Kyriakos P Papadopoulos, David S Siegel, David H Vesole, Peter Lee, Steven T Rosen, Naseem Zojwalla, Joseph R Holahan, Susan Lee, Zhengping Wang, Ashraf Badros. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2015 Mar; 33(7):732-9. doi:
10.1200/jco.2013.52.3522. [PMID: 25225420] - Ravi Vij, Michael Wang, Sundar Jagannath, Ruben Niesvizky, Andrzej J Jakubowiak, Edward Kavalerchik, Mei Huang, David S Siegel. Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.
Leukemia & lymphoma.
2015; 56(10):2959-61. doi:
10.3109/10428194.2015.1020801. [PMID: 25699653] - Meletios A Dimopoulos, Paul G Richardson, Philippe Moreau, Kenneth C Anderson. Current treatment landscape for relapsed and/or refractory multiple myeloma.
Nature reviews. Clinical oncology.
2015 Jan; 12(1):42-54. doi:
10.1038/nrclinonc.2014.200. [PMID: 25421279] - Ajai Chari, Daher Hajje. Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.
BMC cancer.
2014 Dec; 14(?):915. doi:
10.1186/1471-2407-14-915. [PMID: 25471129]